Pharma stock that offers generic formulations and API products, including anti-diabetics, immunosuppressants, and many more in focus after receiving US FDA’s approval for Key Cancer drugs.
Price Movement
With a market capitalization of ₹38,251 Crores the shares of Biocon rallied to today’s day high of ₹324.90 on the BSE on 5 march, 2025, up by 3.1% from its previous day closing price of ₹314.80.
Reason
Biocon Pharma Limited (the fully owned subsidiary) of Biocon received final approval for its following ANDAs from the U.S. Food and Drug Administration (U.S. FDA):
- Lenalidomide Capsules – It is a medication used to treat types of multiple myeloma, mantle cell lymphoma, follicular lymphoma, marginal zone lymphoma, and anemia in myelodysplastic syndromes (MDS) in adults.
- Dasatinib Tablets- This medication is used to treat certain types of cancer (chronic myeloid leukemia-CML, acute lymphoblastic leukemia-ALL). It works by slowing or stopping the growth of cancer cells
- Biocon Pharma Limited also received tentative approval of its ANDA for Rivaroxaban Tablets USP. Rivaroxaban is used in the treatment of deep vein thrombosis and pulmonary embolism to reduce the risk of stroke and systemic embolism in nonvalvular atrial fibrillation,.etc.
These approvals further add to Biocon’s portfolio of vertically integrated, complex drug products
Also read: Power transmission stock jumps 4% after receiving ₹500 Cr order from Power Grid Corpo
Financial Highlights
The company reported a revenue of ₹3,821 crores in Q3 FY25 which is 6.43% up from the previous quarter of ₹3,590 crores. The company has maintained a healthy average operating profit margin of 20%. Its net profit increased by over 200% (₹81 crores) in the latest quarter of Q3 FY25 as compared to the previous quarter of only ₹27 crores.
The company’s consolidated net profit dropped to ₹25.1 crores in Q3 FY25, compared to ₹660 crores in Q3 FY24, while revenue stood at ₹3,821 crore in the latest quarter, down from ₹3,954 crore on a YoY basis.
Future Plans
The company plans to list its key Biosimilar business by March, 2026 and launch its five new biosimilars in the USA market in the new fiscal year by April, 2025 and the management are optimistic about scoring double-digit market share. It aims to be one of the top three biosimilar companies globally through strategic launches and partnerships.
About Company
Biocon Limited, together with its subsidiaries, engages in the manufacture and sale of biotechnology products and research services in India, Brazil, Singapore, and internationally. It operates through four segments: Generics, Novel Biologics, Biosimilars, and Research Services.
The company offers generic formulations and API products, including anti-diabetics, immunosuppressants, multiple sclerosis, anti-cancer/oncology, and other products; novel biologics products, such as head and neck cancer molecule; novel pipeline products comprising psoriasis molecules; and biosimilars products consisting of insulins, trastuzumab, pegfilgrastim, and bevacizumab.
It also provides integrated discovery, development, and manufacturing services to pharmaceutical, biotechnology, animal healthcare, consumer goods, and agrochemical companies. Biocon Limited was incorporated in 1978 and is headquartered in Bengaluru, India.
Written by Satyajeet Mukherjee
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
